Homology Medicines Advances First Gene Editing Development Candidate into IND-Enabling Studies for Pediatric Patients with Phenylketonuria
Homology Medicines, Inc. (FIXX)
Last homology medicines, inc. earnings: 3/12 04:10 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
- Data Demonstrates Highly Efficient and Selective In Vivo Gene Editing in a Humanized Murine Model - - New Internal GMP Manufacturing Capability to Support Gene Therapy and Gene Editing Programs - BEDFORD, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has nominated an in vivo gene editing development candidate and initiated IND-enabling studies for the treatment of pediatric patients with phenylketonuria (PKU). Homology also completed its internal GMP manufacturing facility with capabilities to support both gene editing and gene therapy programs. “Starting IND-enabling studies with an in vivo, nuclease-free gene editing candidate is an important milestone for Homology and achieves a key 2018 corporate goal,” said Albert Seymour, Ph.D., Chief Scientific Officer of Homology Medicines. “Our dual platform has enabled us to progress specific genetic medicine programs for PKU that may address two
Show less
Read more
Impact Snapshot
Event Time:
FIXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FIXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FIXX alerts
High impacting Homology Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
FIXX
News
- Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million [Yahoo! Finance]Yahoo! Finance
- Homology Medicines Declares Distribution to Common StockholdersGlobeNewswire
- Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law FirmGlobeNewswire
- HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXXBusiness Wire
- Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases [Yahoo! Finance]Yahoo! Finance
FIXX
Earnings
- 11/14/23 - Miss
FIXX
Sec Filings
- 3/27/24 - Form 8-K
- 3/22/24 - Form 8-K/A
- 3/20/24 - Form 8-K
- FIXX's page on the SEC website